安科生物：12月26日召开董事会会议

Group 1 - The core point of the article is that Anke Bio (SZ 300009) held its first board meeting of the ninth session on December 26, 2025, where it reviewed the proposal for appointing the company's audit director [1] - For the first half of 2025, Anke Bio's revenue composition was as follows: 73.51% from genetic engineering drugs, 16.77% from other businesses, and 9.72% from external patches [1] - As of the report date, Anke Bio's market capitalization was 16.3 billion yuan [1]